Reply to 'preoperative pet/ct in early-stage breast cancer: Is the tnm classification enough?'

Annals of Oncology

Volumn 24, Issue 3, 2013, Pages 852-853

  Bernsdorf, M ^a  

^a University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; COST UTILITY ANALYSIS; DIAGNOSTIC ACCURACY; DISTANT METASTASIS; EARLY CANCER; HIGH RISK PATIENT; HUMAN; LETTER; PATIENT IDENTIFICATION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL;

EID: 84874554886     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt006     Document Type: Letter

References (5)

1. Gilardi L, Fumagalli L, Paganelli G. Preoperative PET/CT in early-stage breast cancer: is the TNM classification enough? Ann Oncol 2013; 24: 852.
2. Fuster D, Duch J, Paredes P et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008; 26(29): 4746-4751.
3. Groheux D, Hindie E, Delord M et al. Prognostic Impact of 18FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst 2012; 104(24): 1879-1887.
4. Bernsdorf M, Berthelsen AK, Wielenga VT et al. Preoperative PET/CT in early-stage breast cancer. Ann Oncol 2012; 23(9): 2277-2282.
5. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98(19): 10869-10874.